Skip to main content
Psychedex

5-MeO-DiPT

5-methoxy-N,N-diisopropyltryptamine

6Node page

what any key link opens

psx:substance/5-meo-dipt/claim/ddbb5f8d-7c59-4340-bdcd-47f710bc5830

claim2026-04-26workinginconclusive

derived from · upstream

feeds · downstream

Closure of psx:substance/5-meo-dipt/claim/ddbb5f8d-7c59-4340-bdcd-47f710bc5830: 42 upstream, 157 downstream.

psx:substance/5-meo-dipt/claim/ddbb5f8d-7c59-4340-bdcd-47f710bc5830
├─ used  src/doi:10.1111/j.1360-0443.2006.01573.x  Designer drugs as a cause of homicide.
  ├─ informed_by  claim/a2a0982a-a0a7-4284-9e94-250e8acedca9  Claim in clinical-evidence — inconclusive  working
  ├─ informed_by  claim/472f2908-5e54-49ae-9a28-7d322bb7d85b  Claim in clinical-evidence — inconclusive  working
  ├─ informed_by  claim/34de1c8c-ac8d-470f-bc0a-423ead592905  Claim in clinical-evidence — supported
  ├─ informed_by  claim/dacb20b7-c8ff-4806-8a01-6f916e1ac066  Claim in clinical-evidence — inconclusive  working
    ├─ used  src/url:9892e09d170feef9  Foxy Fast Facts (National Drug Intelligence Center)
    ├─ used  src/url:3b5e662beee146a6  5-MeO-DiPT Basics (Erowid)
    ├─ used  src/pmid:6949674  N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity.
    ├─ used  src/pmid:18072099  Foxy methoxy: a new drug of abuse.
    ├─ used  src/pmid:15455477  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    ├─ used  src/doi:10.1002/npr2.12161  Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.
    ├─ used  src/pmid:16460788  Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
    ├─ used  src/doi:10.1097/FBP.0000000000000841
    ├─ used  src/pmid:16510126  Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
    ├─ used  src/doi:10.3390/ijms21239279  Toxicology and Analysis of Psychoactive Tryptamines.
    ├─ used  src/doi:10.1007/s12640-016-9654-0  Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.
    ├─ used  src/doi:10.1007/s11419-018-0433-x  Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult rats
    ├─ used  src/doi:10.1208/s12248-008-9028-5  Indolealkylamines: biotransformations and potential drug-drug interactions
    ├─ used  src/doi:10.3760/cma.j.issn.0254-6450.2018.06.011  Prevalence of HIV infection and related risk behaviors among male new-type drug users in Qingdao, Shandong province.
    ├─ used  src/doi:10.1080/09540121.2016.1140888  Recreational drug use and related social factors among HIV-positive men in Japan.
    ├─ used  src/pmid:12678045  Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.
    ├─ used  src/url:a15d151167081306  UK Psychoactive Substances Act 2016 and 5-MeO compounds
    ├─ used  src/doi:10.1038/s41380-024-02506-8  Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties
    ├─ used  src/pmid:151182  5-MeO-DiPT (CID 151182)
    ├─ used  src/url:d848927e0add8d2e  5-MeO-DiPT Physical Properties
    ├─ used  src/doi:10.1016/j.euroneuro.2016.05.001  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
    ├─ used  src/doi:10.1016/j.neures.2025.04.006  A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).
    ├─ used  src/pmid:15516287  A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS.
    ├─ used  src/doi:10.1124/jpet.122.001454  Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERT
    ├─ used  src/doi:10.1371/journal.pone.0009019  Psychedelics and the human receptorome
    ├─ used  src/doi:10.1038/s41586-024-07403-2  Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
    ├─ used  src/pmid:10638639  The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.
    ├─ used  src/doi:10.1002/dta.2197  Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine
    ├─ used  src/doi:10.1186/1940-0640-8-9  Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N,N-diisopropyltryptamine abuser.
    ├─ used  src/doi:10.1124/jpet.111.179705  Abuse liability profile of three substituted tryptamines
    ├─ used  src/doi:10.1021/acsptsci.0c00173  Discriminative Stimulus Effects of Substituted Tryptamines in Rats
    ├─ used  src/pmid:18198474  Neuropsychotoxicity of abused drugs: molecular and neural mechanisms induced by methamphetamine, MDMA, and 5-MeO-DiPT.
    ├─ used  src/doi:10.1007/s00204-015-1513-x  The hallucinogenic world of tryptamines: an updated review.
    ├─ used  src/doi:10.3109/15563650.2011.615318  Clinical toxicology of newer recreational drugs.
    ├─ used  src/doi:10.1016/j.pharep.2018.04.001  The effect of repeated-intermittent exposure to 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) during adolescence on learning and memory in adult rats.
    ├─ derived_from  gen/f79a0760-4821-4b38-aa88-67860c88f76e  Generation — pipeline-v5
    └─ generated_by  pub/c4e3960c-db63-4693-8b50-fc0b48041b2a  Publication — backfill
├─ informed_by  section/clinical-evidence.full@1
  ├─ used  version/1  Revision 1
  ├─ used  claim/4dc61c34-a48d-4237-a9a8-7f03824dfbdb  Claim in safety — inconclusive  working
  ├─ used  claim/fd08b46c-99b5-440b-860f-6b71e59a1c6e  Claim in safety — inconclusive  working
  ├─ used  claim/c71b24ca-980e-4c02-a507-a818ca32e23e  Claim in clinical-evidence — inconclusive  working
    ├─ derived_from  issue/notice@c5e98aeaee01  Issued notice
    ├─ derived_from  issue/info_card@c16ade557a55  Issued info_card
    ├─ derived_from  issue/emergency@3f0909c25c71  Issued emergency
    ├─ derived_from  issue/info_card@fde2b9b993c1  Issued info_card
    ├─ derived_from  issue/emergency@c15c760aabf6  Issued emergency
    ├─ informed_by  section/safety.full@1
      ├─ used  claim/ae206d39-3a07-46f9-bd55-645c7effe613  Claim in summary — inconclusive  working
      ├─ used  claim/3655ca10-0d79-4dc1-be96-5867a6ce30d5  Claim in history — inconclusive  working
      ├─ used  claim/fc41d521-02e9-4915-b7c0-72f33772b44f  Claim in summary — supported
      ├─ used  claim/f7220fb3-49f1-4cf4-8aa2-41744d65caf4  Claim in history — inconclusive  working
      ├─ used  claim/e28fe4df-65d1-469d-8242-27e6e847d994  Claim in summary — inconclusive  working
      ├─ used  claim/7d3c77ba-a71d-4344-ab87-3af14dcfa340  Claim in history — inconclusive  working
      ├─ used  claim/70485aeb-cdd1-4b48-8cfc-0ceb3174f677  Claim in history — inconclusive  working
      ├─ used  claim/50e31dc9-612a-4d23-ae73-6e6622281d93  Claim in summary — partially_supported
      ├─ used  claim/a4217ba7-a665-48d7-81ae-7eefd6ded135  Claim in history — inconclusive  working
      ├─ used  claim/740b99a4-fcaa-497f-8a7b-3cc282d0feab  Claim in history — supported
      ├─ used  claim/63fe453e-013c-480a-b580-948dd67358b0  Claim in summary — inconclusive  working
      ├─ used  claim/70f15035-57c3-41fd-bb1a-a0c117503ed1  Claim in history — inconclusive  working
      ├─ used  claim/683be6e7-4674-4447-910c-c17f5d5300c7  Claim in summary — supported
      ├─ used  claim/720087da-5569-41e6-812b-b8c9353f09f2  Claim in history — supported
      ├─ used  claim/c6c122e0-9135-4daa-bca2-4cb57ad9a006  Claim in summary — inconclusive  working
      ├─ used  claim/2c1641aa-4763-4015-a9e9-8927ec18637e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/1c17dd06-f5db-41de-bea4-261021876c98  Claim in summary — inconclusive  working
      ├─ used  claim/1bd12c0c-a7a8-46bf-a83f-413719b08966  Claim in pharmacology — inconclusive  working
      ├─ used  claim/58a84a5e-c9fd-4a8f-ae79-84eb7b1ac4fd  Claim in summary — inconclusive  working
      ├─ used  claim/2c164de3-3cbe-4bbd-af86-c7cec61a2048  Claim in summary — inconclusive  working
      ├─ used  claim/0fadba0d-6c98-40d9-a76e-76324aacbf9e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/21309424-fe98-469b-b53b-55659b49cda0  Claim in pharmacology — inconclusive  working
      ├─ used  claim/e7041354-e873-41cb-bb8f-ac6b7128b957  Claim in pharmacology — inconclusive  working
      ├─ used  claim/d6ed0078-484d-410e-899a-031aab282ca6  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/ab95418a-117f-4804-b0ec-43d4e3349477  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/fab3791c-58af-4146-9242-8842647a5d5a  Claim in summary — partially_supported
      ├─ used  claim/055aa1d3-2a7c-4dfd-821e-d166c9df1eca  Claim in summary — partially_supported
      ├─ used  claim/a74fb411-f1c1-46ec-9187-be7d20d17afe  Claim in pharmacology — supported
      ├─ used  claim/7abf44d3-858e-4543-91b1-1db5732fb091  Claim in pharmacology — supported
      ├─ used  claim/aedc5643-dfec-4aa7-960c-2998c4ff9dee  Claim in pharmacology — partially_supported
      ├─ used  claim/515f6810-5a56-4c55-a5a2-820a641947b9  Claim in receptor-pharmacology — supported
      ├─ used  claim/d0241bef-edc5-4bd0-b11e-19bd5fe68ecc  Claim in receptor-pharmacology — supported
      ├─ used  claim/85605498-1037-4f39-b197-dea9bc282632  Claim in summary — inconclusive  working
      ├─ used  claim/f126a165-7fe9-4d22-b92a-78a3953d0918  Claim in pharmacology — inconclusive  working
      ├─ used  claim/5b9931f9-e3e2-4446-8b04-e2d750359e85  Claim in safety — inconclusive  working
      ├─ used  claim/ff119c4a-8856-4961-b64a-0ac608bd6692  Claim in summary — partially_supported
      ├─ used  claim/f14283ce-3e2a-4328-ace7-865d82790f12  Claim in pharmacology — not_supported  working
      ├─ used  claim/9f048608-ddf8-40e8-b782-7b8af9273ae6  Claim in safety — supported
      ├─ used  claim/ef9d1c59-cbcb-4a9c-8098-7ead24eb042b  Claim in summary — inconclusive  working
      ├─ used  claim/9af84f14-883f-4be2-aeb9-b40692509fcd  Claim in pharmacology — inconclusive  working
      ├─ used  claim/fa604134-e53d-449c-9e2d-bc680ef3ff4f  Claim in pharmacology — inconclusive  working
      ├─ used  claim/95685cb9-c89f-4471-a733-520e6e18f510  Claim in safety — inconclusive  working
      ├─ used  claim/61e25c08-ae48-496f-9007-5c043a1b3304  Claim in safety — inconclusive  working
      ├─ used  claim/2045e07e-c2d8-48a9-aae8-cfc3e76e9712  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/01e6c548-83d1-401c-aa57-b1c937b5e63d  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/8f3268a4-2dbc-4ff3-89de-119efeaf8803  Claim in summary — inconclusive  working
      ├─ used  claim/6e2fdfaa-dc3d-42c8-b3cf-61d231fde22e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/2fc7db5f-e62a-4a1f-a043-968b0bebdc14  Claim in pharmacology — inconclusive  working
      ├─ used  claim/7b91ea1a-ad0e-4151-816d-91741934d321  Claim in safety — inconclusive  working
      ├─ used  claim/6182a66d-9412-4296-89ca-f388dd1e6f90  Claim in safety — inconclusive  working
      ├─ used  claim/f6ace933-a2e4-4ab8-a71e-5d63e8bde6b8  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/c24392ae-e19e-4a0a-ae9c-b1d7ba62def9  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/91d6a456-9849-4f12-bb95-7256507fbaef  Claim in summary — inconclusive  working
      ├─ used  claim/e37ab18b-b4c8-4df3-a08c-351c164c7714  Claim in safety — inconclusive  working
      ├─ used  claim/ce474baa-88b0-40f3-8da4-8085b829ed8a  Claim in safety — inconclusive  working
      ├─ used  claim/51fe5bf6-3c38-40f1-b907-9408724bcef0  Claim in summary — inconclusive  working
      ├─ used  claim/37a1abf9-e0f9-40cb-80bb-a15987433cfb  Claim in safety — supported
      ├─ used  claim/bd66e875-c416-4ad1-97e7-1e6095442b64  Claim in safety — inconclusive  working
      ├─ used  claim/c700ea7f-b88e-4421-b4c0-7ba4039fad03  Claim in summary — inconclusive  working
      ├─ used  claim/066b467b-29d1-4903-97a8-b79f0934ac19  Claim in pharmacology — inconclusive  working
      ├─ used  claim/96c553eb-00d2-484d-8ce3-653f85e6e68e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/ac11cb65-691b-4ec4-813d-55633075562d  Claim in pharmacology — inconclusive  working
      ├─ used  claim/3a591b6f-8492-4c7f-b62a-35a0b2e3537e  Claim in neuroscience — inconclusive  working
      ├─ used  claim/94d1ec8b-2793-4f95-9d29-836f54585dfa  Claim in neuroscience — inconclusive  working
      ├─ used  claim/1bc6d09e-b5d6-4941-bd93-8f3510fdc403  Claim in safety — inconclusive  working
      ├─ used  claim/c0102f17-0464-40a2-bf4a-91bd9ddb1867  Claim in safety — inconclusive  working
      ├─ used  claim/34c43654-dab5-4dda-9a80-33d2c104d50f  Claim in safety — inconclusive  working
      ├─ used  claim/112cf22f-d891-4b6c-a1e5-e0f8e8207abc  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/b224fb46-f31b-4b71-b811-76c61f2dad29  Claim in summary — supported
      ├─ used  claim/644ebe2b-de53-470d-9bab-cb6cb7f20ae8  Claim in pharmacology — supported
      ├─ used  claim/d2658ef7-98f0-4587-9c1c-39aea201670e  Claim in pharmacology — inconclusive  working
      ├─ used  claim/6d40ff4c-6b5b-4c98-a6f4-0f84f5645404  Claim in pharmacology — inconclusive  working
      ├─ used  claim/f76aaeab-fd01-4476-ae25-b18da2012002  Claim in neuroscience — partially_supported
      ├─ used  claim/0bf3baf4-9b4f-49eb-8a53-04eabebcd4b4  Claim in neuroscience — inconclusive  working
      ├─ used  claim/1ef8a13d-d91d-4bb2-b16a-ac638833f5dc  Claim in safety — supported
      ├─ used  claim/c765b387-6455-4a11-a62f-fc3994bcc8ca  Claim in safety — not_supported  working
      ├─ used  claim/0e9312a3-fe14-4618-b62e-8124e61f043f  Claim in safety — supported
      ├─ used  claim/2e339a00-f91f-44f2-a279-fa694cb2dbe4  Claim in receptor-pharmacology — supported
      ├─ used  claim/03badc22-f881-4ba0-8977-019e7954ce84  Claim in summary — inconclusive  working
      ├─ used  claim/fb8f3629-9971-48c9-8ed9-f92a94f8d16d  Claim in safety — inconclusive  working
      ├─ used  claim/400b4734-173e-4eea-b689-356246ce2bb4  Claim in summary — supported
      ├─ used  claim/fdd4b07d-cecb-414e-990b-ae7b43ee2970  Claim in safety — supported
      ├─ used  claim/f246a5c4-bb6e-4bb0-8157-3f9bf47a39b3  Claim in summary — inconclusive  working
      ├─ used  claim/02dd95de-44d5-4fe1-8b4c-9f6d7144ca94  Claim in pharmacology — inconclusive  working
      ├─ used  claim/74dc0476-9e50-4c75-a24e-5bfed784fdc0  Claim in pharmacology — inconclusive  working
      ├─ used  claim/fa31a42a-6cbc-41dd-8756-25eaacd34ff6  Claim in safety — inconclusive  working
      ├─ used  claim/0cbd137f-d465-4418-9145-fc0e8bd39ea5  Claim in safety — inconclusive  working
      ├─ used  claim/37478abf-2a21-4432-a095-d6b670b9d5c0  Claim in safety — inconclusive  working
      ├─ used  claim/025a3b7c-cda3-416e-8847-113cc7640edc  Claim in safety — inconclusive  working
      ├─ used  claim/0bc2cd48-8108-4683-b064-1bd4b4e78088  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/870224f6-62b3-4173-97f0-eb571227127e  Claim in summary — partially_supported
      ├─ used  claim/1883da13-f316-4e55-b0a2-84ddd0a88581  Claim in pharmacology — supported
      ├─ used  claim/5705ad4b-a2c5-4b9d-bc32-031fc08ed03b  Claim in pharmacology — supported
      ├─ used  claim/8de6a2f3-79f4-4066-9a75-71f51903c103  Claim in safety — supported
      ├─ used  claim/2411f0f2-4a60-49b1-be31-e0f7eb4bcf14  Claim in safety — partially_supported
      ├─ used  claim/5c0ed76f-8d84-41d3-a822-bba722215c4d  Claim in safety — supported
      ├─ used  claim/e1a6ac95-f6fd-4da3-aca1-ca8e7275752f  Claim in safety — supported
      ├─ used  claim/bbdc52f3-094d-4915-976e-8f10439636be  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/333800ec-9f3d-421a-9cb8-53b2352426f9  Claim in history — inconclusive  working
      ├─ used  claim/10dd0cab-3725-492f-a7aa-defa0838a32b  Claim in history — inconclusive  working
      ├─ used  claim/4febe8c9-4d56-4f50-8116-edc86aa29468  Claim in history — inconclusive  working
      ├─ used  claim/f1c7e241-7f05-4bc2-9faa-93905c2e7fb7  Claim in history — supported
      ├─ used  claim/591e6208-bd14-4611-8f71-686a15830341  Claim in chemistry — inconclusive  working
      ├─ used  claim/065b147f-d326-40c8-b66a-81fe9aeab1af  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/b9cf5182-762e-4677-904f-4a7faff63a06  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/565359cf-fe7b-44b9-a510-608f7e086d1a  Claim in chemistry — supported
      ├─ used  claim/dba1885b-44cb-4b23-8692-426ac341b246  Claim in comparative-pharmacology — supported
      ├─ used  claim/3706a3a7-7eb9-4e78-ade8-ac6b46a2540b  Claim in comparative-pharmacology — supported
      ├─ used  claim/712418b6-93e8-42a0-99f0-866595bd11de  Claim in chemistry — inconclusive  working
      ├─ used  claim/dda6e0fc-2983-4bf2-96ec-f3755e8c02df  Claim in chemistry — inconclusive  working
      ├─ used  claim/d7492c93-4dc5-4fd3-9356-a2eb17e79432  Claim in pharmacology — inconclusive  working
      ├─ used  claim/ed5cd436-a07e-4c88-8eb7-442147f62518  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/bcf9d54c-bd54-4dbf-9c4b-e84a6564805f  Claim in pharmacology — inconclusive  working
      ├─ used  claim/0d904d3e-105b-4a00-86fc-c3bf6f68ff7a  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/cfa199b5-8934-4ca0-a943-c9ba793e2f94  Claim in pharmacology — inconclusive  working
      ├─ used  claim/90f8b60a-d58c-4cca-a1ba-1a3e0ffffa20  Claim in pharmacology — inconclusive  working
      ├─ used  claim/55b0c5cb-a51c-4a16-9402-c3ec7fa4fc72  Claim in neuroscience — inconclusive  working
      ├─ used  claim/c32a3a2b-bda1-405a-bd37-c050267746a5  Claim in pharmacology — supported
      ├─ used  claim/311ff3fa-9d71-4d8b-87f7-38e5fd4f0494  Claim in pharmacology — inconclusive  working
      ├─ used  claim/8103c255-a6e7-45e3-b1f6-3ed6db027a29  Claim in neuroscience — supported
      ├─ used  claim/6d27d936-1de0-429a-b8bc-622911330a11  Claim in pharmacology — inconclusive  working
      ├─ used  claim/d050728d-5989-4a8e-8d17-eea27eab0246  Claim in pharmacology — inconclusive  working
      ├─ used  claim/64a1b5d7-5813-4aeb-b4fe-872c4f8ef0f3  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/b05dae3f-3bbb-4135-a58c-4f6921724ffc  Claim in pharmacology — inconclusive  working
      ├─ used  claim/aec11414-b2e2-48c7-8a1c-22840bb30da4  Claim in pharmacology — partially_supported
      ├─ used  claim/994744e5-88d8-4366-8731-d14380a052ba  Claim in pharmacokinetic-detail — partially_supported
      ├─ used  claim/fab95347-af9d-4acb-950c-c75cd1af21ab  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/66693953-8976-4339-91ec-45281146dca0  Claim in receptor-pharmacology — supported
      ├─ used  claim/8893d3fb-dbdb-4517-b890-f1dcfe575f56  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/b9fe682f-36e9-4f46-bf7f-bdddf5337953  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/e093dd9e-09ed-4ef2-be48-0b38aeab880d  Claim in receptor-pharmacology — inconclusive  working
      ├─ used  claim/fc378b18-886d-4053-9343-ed3886408d79  Claim in comparative-pharmacology — inconclusive  working
      ├─ used  claim/f9a6ebf4-bac1-4af3-92a0-f77cc56650ef  Claim in receptor-pharmacology — supported
      ├─ used  claim/533d2af0-3ea6-41c9-a428-a3c4948a952d  Claim in comparative-pharmacology — supported
      ├─ used  claim/aadd53af-d36f-4b7a-90fe-83e1fee3c474  Claim in pharmacokinetic-detail — inconclusive  working
      ├─ used  claim/172cd370-91a0-42e0-8808-a830569f4a9a  Claim in pharmacokinetic-detail — supported
      ├─ used  claim/f677560a-aba3-4064-a3c5-c43971938e50  Claim in safety — inconclusive  working
      ├─ used  claim/33893cb5-1363-413a-925d-bd362eab5fde  Claim in safety — inconclusive  working
      ├─ used  claim/e6a89195-9674-446c-9bd1-f2ac30a5ae4f  Claim in safety — inconclusive  working
      ├─ used  claim/b02b1f96-27ee-437f-a261-0260f2ec8df1  Claim in safety — inconclusive  working
      ├─ used  claim/72e50f9b-51d8-465e-8abf-6e20ad04d2e9  Claim in safety — inconclusive  working
      ├─ used  claim/a92331d8-135a-419f-9bd3-f47008fca992  Claim in safety — inconclusive  working
      ├─ used  claim/0978ebab-b79d-476a-aa32-c2957e7fd4ec  Claim in safety — inconclusive  working
      ├─ used  claim/4b7c7f5a-dc1f-406a-95ff-e27a4cde03c2  Claim in safety — inconclusive  working
      ├─ used  claim/ac2b81f7-8e3d-452e-8bab-2087e3bb327c  Claim in safety — inconclusive  working
      └─ used  claim/3e5b1b0c-32c2-47e7-8d09-c3b6f5f9d4a5  Claim in comparative-pharmacology — inconclusive  working
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

3622 with DOI

3 strong · 26 moderate · 7 weak

Compilations

12026-04-26T14:29:35.748Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:30:14.317Z

notice · info card · emergency

Searches

283 with no results

queries and counts on the build

Claims checked

16849 supported

49 supported · 119 not

Correspondence

0received

consent field ships in Phase 4

Edges

446

derivations recorded for this entity

Complete over 36 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5-meo-dipt/archive

2Build

one panel per compilation run

generation run 2026-04-26

53 min completedmodel pipeline-v5plan not recordedrun/7f085aee…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen131
selected by the model51
consumed as sources36

Verification

claims checked168
supported38
partially supported11
not supported2
inconclusive117
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
36 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
28 searches — query, source, results, what was kept and why
28 searches for this run
#sourcequeryseenkeptrationale
1OpenAlex5-MeO-DiPT tryptamine psychedelic pharmacology104Selected highly-cited papers with direct relevance to 5-MeO-DiPT pharmacology and tryptamine class context
2PubMedfoxy methoxy tryptamine Schedule I DEA scheduling22Primary regulatory documents for US legal status
3PubMed · absence5-MeO-DIPT SERT 5-HT2A 5-HT1A receptor0——
4PubMed · absence5-methoxy-N,N-diisopropyltryptamine receptor binding serotonin affinity0——
5OpenAlex5-MeO-DiPT foxy methoxy receptor binding pharmacology104Key pharmacology papers with receptor binding data and metabolism data
6PubChem5-MeO-DiPT11Confirms chemical identity; SMILES not returned but all other identity fields verified
7PubMed5-MeO-DiPT foxy methoxy pharmacology1515All selected as directly relevant to 5-MeO-DiPT pharmacology, toxicology, legal status, or case reports
8PubMed5-methoxy diisopropyltryptamine head twitch response serotonin hallucinogen31Fantegrossi 2006 is key in vivo pharmacology paper with receptor binding assays
9WebSearch/WebFetch5-MeO-DiPT UK Psychoactive Substances Act 2016102—
10PubMedShulgin Carter 1980 DiPT 5-MeO-DiPT original paper11—
11WebSearch5-MeO-DiPT Ki binding affinity nM radioligand10——
12PubMedstructural pharmacology 5-methoxytryptamines Nature 202411—
13PubMed5-MeO-DIPT GC-MS LC-MS urinalysis detection forensic11—
14PubMedtryptamine hallucinogen discriminative stimulus abuse liability43—
15PubMed/OpenAlexreceptor binding profiles novel tryptamines54—
16WebSearch5-MeO-DiPT Canada Controlled Drugs Substances Act10——
17PubMedfoxy methoxy tryptamine Schedule I DEA scheduling22—
18WebSearch5-MeO-DiPT Japan Narcotics Control Law Schedule 2004 2005101—
19PubMed5-MeO-DiPT metabolism pharmacokinetics11—
20PubMed5-MeO-DIPT Japanese drug abuse psychosis case11—
21WebFetch—11—
22WebSearch5-MeO-DiPT PCP lethal interaction10——
23Crossref/verify_doiDOI 10.1111/j.1360-0443.2006.01573.x11—
24WebFetch—11—
25WebSearch5-MeO-DiPT UK Psychoactive Substances Act Australia102—
26WebFetch—11—
27ClinicalTrials.gov · absence5-MeO-DiPT foxy methoxy tryptamine0——
28WebSearch5-MeO-DiPT CAS number SMILES melting point physical properties101—
168 claims by section — every cited sentence, checked against its source
safety46 · 12 ok

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Li et al. confirmed acute toxic effects in mice but did not report lethal dose parameterssupported

    AMT showed acute toxic effects in mice. fbp.0000000000000841

  • Reported acute adverse effects from case reports, government data, and toxicology reviews include:supported

    Review of tryptamine toxicology; morbidity considerable and underestimated. ijms21239279

  • Reported acute adverse effects from case reports, government data, and toxicology reviews include:supported

    Comprehensive review on tryptamine hallucinogens including AMT; physiological and toxicological effects. s00204-015-1513-x

  • Reported acute adverse effects from case reports, government data, and toxicology reviews include:supported

    Serotonergic effects predominate in toxicity; management primarily supportive. 15563650.2011.615318

  • Noworyta-Sokołowska et al. demonstrated in rats that 5-MeO-DiPT at 5, 10, and 20 mg/kg produced DNA single- and double-strand breaks (detected by comet assay) persisting up to 60 days after treatment, along with decreased DA, DOPAC, and HVA tissue content — suggesting either adaptive changes in dopamine turnover or damage to dopaminergic terminals.supported

    DNA strand breaks persist 60 days post-treatment indicating neurotoxicity. s12640-016-9654-0

  • Repeated-intermittent adolescent exposure produced in adult rats: caspase-3 activation (an apoptotic marker), oxidative DNA damage, altered expression of 5-ht1a and 5-HT₂A receptor genes, and decreased cell viability in brain tissuesupported

    Adolescent repeated 5-MeO-DIPT exposure: caspase-3 activation; oxidative DNA damage. Long-term neurotoxicity in developing brain. s11419-018-0433-x

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • No animal self-administration studies have been conducted. dipt showed hallucinogen-like discriminative stimulus effects in rats, establishing behavioral abuse-liability potential without addressing compulsive use or dependence.supported

    DOM used as training drug. DIPT fully substituted at ED50=1.94 mg/kg. jpet.111.179705

  • MAOIs represent the most dangerous interaction class. Monoamine oxidase inhibitors block serotonin catabolism; combined with 5-MeO-DiPT's SERT inhibition (blocking reuptake) and direct 5-HT₁A/5-HT₂A agonism (postsynaptic activation), the result is a three-mechanism convergence on serotonergic overactivationsupported

    DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5

  • Added to 5-MeO-DiPT's SERT inhibition and direct 5-HT agonism, co-administration represents a credible serotonin syndrome risk. tramadol also lowers seizure threshold.partially supported

    DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • CYP2D6 inhibitors — including fluoxetine, paroxetine, and bupropion — impair 5-MeO-DiPT O-demethylation, producing phenocopied poor metabolizer kinetics with elevated parent compound exposure.supported

    CYP2D6 polymorphism represents additional risk factor. DDIs can occur at pharmacokinetic and pharmacodynamic levels. s12248-008-9028-5

  • Claim in safety — not_supportednot supportedworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • Claim in safety — inconclusiveinconclusiveworking →

  • cytochrome P450 2D6 poor metabolizer status — whether genetic or medication-induced — increases exposure and toxicity risk.supported

    CYP2D6 polymorphism represents additional risk factor. DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5

  • Claim in safety — inconclusiveinconclusiveworking →

  • Pregnancy and breastfeeding are absolute contraindications given absent reproductive safety data and documented genotoxicity in animal models.supported

    DNA strand breaks persist 60 days post-treatment indicating neurotoxicity. s12640-016-9654-0

pharmacology34 · 8 ok

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • A notable paradox characterizes its pharmacology: in vitro radioligand binding studies show higher affinity for 5-HT₁A receptors (submicromolar) than for 5-HT₂A or 5-ht2c receptors (micromolar), yet the hallucinogenic behavioral signature in vivo is mediated primarily through 5-HT₂A activation.supported

    Micromolar 5-HT2A/2C affinity but higher 5-HT1A affinity. 5-HT2A primary despite in vitro 5-HT1A selectivity. pmid:16460788

  • Fantegrossi et al. demonstrated that M100907, a selective 5-HT₂A antagonist, potently blocked the 5-MeO-DiPT-induced head-twitch response (HTR) in mice — the standard behavioral proxy for hallucinogenic actionsupported

    5-MeO-DIPT induced head-twitch in mice (M100907-reversible). pmid:16460788

  • In LSD discrimination assays, 5-MeO-DiPT produced 75% generalization — intermediate, not full — suggesting a pharmacological profile partially overlapping with but not identical to classical 5-HT₂A-selective hallucinogenspartially supported

    Partial LSD-discrimination generalization in rats. pmid:16460788

  • Claim in pharmacology — not_supportednot supportedworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • SERT inhibition was confirmed by in vivo microdialysis in rats: dose-dependent increases in extracellular serotonin and decreased 5-HIAA tissue content were observed in striatum, nucleus-accumbens, and frontal cortex at 5, 10, and 20 mg/kg.supported

    5-MeO-DiPT acts as potent SERT inhibitor. s12640-016-9654-0

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Li et al. documented significant effects on dopamine and its metabolites DOPAC and HVA across prefrontal cortex, nucleus accumbens, dorsolateral striatum, and hippocampussupported

    Systematic study of DA, 5-HT and metabolite changes in PFC, NAc, DLS, hippocampus. j.neures.2025.04.006

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Poor metabolizers cannot efficiently O-demethylate 5-MeO-DiPT, potentially resulting in higher systemic exposure and prolonged duration of effectsupported

    CYP2D6 plays important polymorphic role in metabolism of IAA drugs of abuse including tryptamine derivatives. CYP2D6 polymorphism represents additional risk factor. s12248-008-9028-5

  • Concurrent use of CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) may produce the same phenocopy effect.supported

    CYP2D6 polymorphism represents additional risk factor. DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Vorce and Sklerov confirmed urinary detection at 229 ng/mL by LC-MS with a limit of detection of 5 ng/mL.partially supported

    LOD 5-10 ng/mL in blood, 25-1500 ng/mL range in urine by LC-MS. pmid:15516287

summary24 · 9 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • The compound circulated as a "research chemical" from approximately 1999 before the US Drug Enforcement Administration placed it into Schedule I — temporarily in April 2003 and permanently in 2004partially supported

    DEA reported seizures in 12 states by February 2003. pmid:18072099

  • The compound circulated as a "research chemical" from approximately 1999 before the US Drug Enforcement Administration placed it into Schedule I — temporarily in April 2003 and permanently in 2004supported

    DEA permanently places AMT into Schedule I of the CSA based on DHHS recommendation and DEA review. pmid:15455477

  • Claim in summary — inconclusiveinconclusiveworking →

  • 5-MeO-DiPT acts through concurrent serotonin-transporter (SERT) inhibition, 5-ht1a receptor agonism, and 5-ht2a receptor agonismpartially supported

    Micromolar 5-HT2A/2C affinity but higher 5-HT1A affinity. 5-HT2A primary despite in vitro 5-HT1A selectivity. pmid:16460788

  • In vitro binding favors 5-HT₁A (submicromolar affinity) over 5-HT₂A and 5-ht2c (micromolar), yet the selective 5-HT₂A antagonist M100907 abolishes hallucinogen-like behavioral responses in mice, confirming 5-HT₂A as the functionally dominant target for hallucinogenesis. cyp2d6 is the primary O-demethylase, introducing pharmacogenomic variability in exposure and duration.partially supported

    Micromolar 5-HT2A/2C affinity but higher 5-HT1A affinity. 5-HT2A primary despite in vitro 5-HT1A selectivity. pmid:16460788

  • In vitro binding favors 5-HT₁A (submicromolar affinity) over 5-HT₂A and 5-ht2c (micromolar), yet the selective 5-HT₂A antagonist M100907 abolishes hallucinogen-like behavioral responses in mice, confirming 5-HT₂A as the functionally dominant target for hallucinogenesis. cyp2d6 is the primary O-demethylase, introducing pharmacogenomic variability in exposure and duration.partially supported

    Pretreatment with M100907 (0.01 mg/kg) blocked AMT-induced HTR, confirming 5-HT2A involvement. fbp.0000000000000841

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Rodent studies document DNA strand breaks persisting 60 days, caspase-3 activation, and dopaminergic terminal changes at 5–20 mg/kg, though these doses substantially exceed typical human psychoactive doses on a mg/kg basissupported

    DNA strand breaks persist 60 days post-treatment indicating neurotoxicity. s12640-016-9654-0

  • Rodent studies document DNA strand breaks persisting 60 days, caspase-3 activation, and dopaminergic terminal changes at 5–20 mg/kg, though these doses substantially exceed typical human psychoactive doses on a mg/kg basissupported

    Adolescent repeated 5-MeO-DIPT exposure: altered DA, 5-HT, glutamate in adult rats; caspase-3 activation; oxidative DNA damage. s11419-018-0433-x

  • The combination of SERT inhibition and direct 5-HT agonism creates elevated serotonin-syndrome risk, particularly with MAOIs. tolerance follows the rapid tachyphylaxis pattern of serotonergic psychedelics via 5-HT₂A downregulation; no physical-dependence is documentedpartially supported

    DDIs can occur at pharmacokinetic and pharmacodynamic levels leading to serotonin toxicity. s12248-008-9028-5

  • Alexander Shulgin and Michael Carter first synthesized and reported 5-MeO-DiPT in 1980supported

    First published scientific report on DiPT human pharmacology. Reports oral activity and CNS effects. pmid:6949674

comparative-pharmacology12 · 4 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • The shared 5-methoxy substitution confers class-wide selectivity for 5-ht1a over 5-ht2a, while the N,N-dialkyl substituents profoundly modulate potency, duration, serotonin-transporter affinity, and subjective character.supported

    All tested tryptamines showed selectivity for 5-HT1AR over 5-HT2AR; N-group size influences SERT affinity. s41380-024-02506-8

  • The shared 5-methoxy substitution confers class-wide selectivity for 5-ht1a over 5-ht2a, while the N,N-dialkyl substituents profoundly modulate potency, duration, serotonin-transporter affinity, and subjective character.supported

    SAR of 5-methoxytryptamines at 5-HT1A and 5-HT2A. 5-HT1A-selective analogue devoid of hallucinogenic effects. s41586-024-07403-2

  • The bulkier diisopropyl groups reduce 5-HT₂A functional activity relative to the dimethyl variant while increasing SERT interaction.supported

    N-group size influences SERT affinity; HTR mediated primarily by 5-HT2A with 5-HT1A attenuating effect. s41380-024-02506-8

  • In discriminative stimulus assays, DiPT fully substituted for dom in rats, while N,N-diisopropyl tryptamines as a class were less potent than their dimethyl counterparts in DOM discrimination.partially supported

    DOM used as training drug. DIPT fully substituted at ED50=1.94 mg/kg. jpet.111.179705

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

history12 · 3 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • Claim in history — inconclusiveinconclusiveworking →

  • It acquired the street names "Foxy" and "Foxy Methoxy." By February 2003, the DEA had documented law enforcement seizures or reports of abuse in 12 US statessupported

    DEA reported seizures in 12 states by February 2003. pmid:18072099

  • Claim in history — inconclusiveinconclusiveworking →

  • The DEA temporarily placed 5-MeO-DiPT (along with alpha-methyltryptamine) into Schedule I of the Controlled Substances Act on April 4, 2003, citing an imminent hazard to public safetysupported

    DEA temporarily places AMT into Schedule I of the CSA as an imminent hazard to public safety. Effective April 4, 2003. pmid:12678045

  • Permanent Schedule I placement followed in 2004 based on a Department of Health and Human Services scheduling recommendationsupported

    DEA permanently places AMT into Schedule I of the CSA based on DHHS recommendation and DEA review. pmid:15455477

receptor-pharmacology12 · 5 ok

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • 5-HT₂C receptor agonism is confirmed at micromolar concentrationssupported

    Micromolar 5-HT2A/2C affinity. pmid:16460788

  • 5-HT₂C receptor agonism is confirmed at micromolar concentrationssupported

    5-MeO-DiPT acts as potent SERT inhibitor with high affinity at 5-HT1A, 5-HT2A, 5-HT2C. s12640-016-9654-0

  • Kozell et al. characterized the pharmacologic activity of 21 substituted tryptamines at 5-ht2a, 5-ht2c, 5-ht1a, and serotonin-transporter and likely reported 5-MeO-DiPT-specific binding data, but full-text access was unavailable for extractionsupported

    21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. jpet.122.001454

  • The qualitative binding profile from Fantegrossi et al. is: micromolar affinity at 5-HT₂A and 5-HT₂C, submicromolar (higher) affinity at 5-HT₁Asupported

    Micromolar 5-HT2A/2C affinity but higher 5-HT1A affinity. pmid:16460788

  • Claim in receptor-pharmacology — inconclusiveinconclusiveworking →

  • Warren et al. reported cryo-EM structures of 5-HT₁A in complex with 5-MeO-DMT, providing a molecular basis for the 5-HT₁A selectivity observed across the 5-methoxytryptamine classsupported

    Cryo-EM structures of 5-HT1A with 5-MeO-DMT and analogues. SAR of 5-methoxytryptamines at 5-HT1A and 5-HT2A. s41586-024-07403-2

pharmacokinetic-detail10 · 3 ok

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • Caspar et al. corroborated CYP1A2, CYP2C19, cyp2d6, and cyp3a4 involvement in the metabolism of 5-MeO-2-Me-DIPT, a close structural-analog.supported

    CYP1A2, CYP2C19, CYP2D6, CYP3A4 involved in hydroxylation and N-dealkylation. dta.2197

  • Yu reviewed this as a general principle for indolealkylamines: CYP2D6 status alters both pharmacokinetics and drug-drug interaction potential for the class.supported

    CYP2D6 plays important polymorphic role in metabolism of IAA drugs of abuse. DDIs can occur at pharmacokinetic and pharmacodynamic levels. s12248-008-9028-5

  • Vorce and Sklerov validated GC-EI-MS and HPLC-electrospray-MS methods with a limit of detection of 5 ng/mL in blood (pentafluoropropionic derivative for GC-MS) and 5 ng/mL in urine (LC-MS)partially supported

    LOD 5-10 ng/mL in blood, 25-1500 ng/mL range in urine by LC-MS. pmid:15516287

neuroscience8 · 3 ok

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Nakagawa and Kaneko reviewed 5-MeO-DiPT's neuropsychotoxicity using Xenopus oocyte and organotypic slice culture models, documenting effects on the mesocorticolimbic system — the dopaminergic projection from ventral-tegmental-area (VTA) to nucleus accumbens and prefrontal-cortex that underlies reward processing and motivated behavior.supported

    In vitro studies on molecular targets and neural adaptation of 5-MeO-DiPT using Xenopus oocytes and organotypic slice cultures. pmid:18198474

  • Li et al. mapped differential monoamine changes across brain regions following acute 5-MeO-DiPT administration: prefrontal cortex, nucleus accumbens, dorsolateral striatum, and hippocampus all showed significant changes in DA and 5-HT dynamics, with decreased DA and DOPAC tissue content suggesting either adaptive turnover changes or dopaminergic terminal damage.supported

    Systematic study of DA, 5-HT and metabolite changes in PFC, NAc, DLS, hippocampus; DAergic and serotonergic systems both involved. j.neures.2025.04.006

  • Noworyta-Sokołowska et al. demonstrated that 5-MeO-DiPT at 5, 10, and 20 mg/kg in rats increased extracellular serotonin, dopamine, and glutamate across striatum, nucleus-accumbens, and frontal cortexpartially supported

    5-MeO-DiPT acts as potent SERT inhibitor. s12640-016-9654-0

  • Claim in neuroscience — inconclusiveinconclusiveworking →

clinical-evidence6 · 1 ok

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Smolinske et al. provided the first published medical toxicology report of 5-MeO-DiPT abuse, documenting clinical presentations and US poison center data.supported

    Case report and poison center data on 5-MeO-DiPT. pmid:18072099

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

  • Claim in clinical-evidence — inconclusiveinconclusiveworking →

chemistry4 · 1 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • The 5-methoxy substitution confers 5-ht1a selectivity relative to unsubstituted tryptamines, while the N,N-diisopropyl groups increase lipophilicity and modulate receptor affinity and serotonin-transporter interaction.supported

    All tested tryptamines showed selectivity for 5-HT1AR over 5-HT2AR; N-group size influences SERT affinity. s41380-024-02506-8

  • Claim in chemistry — inconclusiveinconclusiveworking →

3Sources

36 consumed · sorted by year · feeds = sections resting on it

Sources 1 to 30
yearsourcetierstatusfeeds
2025A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P · Neuroscience researchdoi:10.1016/j.neures.2025.04.006moderateconsumed2 sections
2025Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice.Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P · Behavioural pharmacologydoi:10.1097/fbp.0000000000000841moderateconsumedcited only
20245-MeO-DiPT (CID 151182)PubChempmid:151182moderateconsumed1 section
20245-MeO-DiPT Physical PropertiesChemsrcurl:d848927e0add8d2eweakconsumedcited only
2024Structural pharmacology and therapeutic potential of 5-methoxytryptamines.Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D · Naturedoi:10.1038/s41586-024-07403-2moderateconsumed2 sections
2024Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory propertiesPuigseslloses P, Nadal-Gratacos N, Ketsela G, et al. · Molecular Psychiatrydoi:10.1038/s41380-024-02506-8moderateconsumed2 sections
2023Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERTKozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, et al. · Journal of Pharmacology and Experimental Therapeuticsdoi:10.1124/jpet.122.001454moderateconsumed1 section
2021Discriminative Stimulus Effects of Substituted Tryptamines in RatsGatch MB, Hoch A, Carbonaro TM · ACS Pharmacology & Translational Sciencedoi:10.1021/acsptsci.0c00173moderateconsumed1 section
2021Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.Hagino Y, Hall FS, Uhl GR, Sora I, Ikeda K · Neuropsychopharmacology Reportsdoi:10.1002/npr2.12161moderateconsumed2 sections
2020Toxicology and Analysis of Psychoactive Tryptamines.Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA · International journal of molecular sciencesdoi:10.3390/ijms21239279moderateconsumed2 sections
2020UK Psychoactive Substances Act 2016 and 5-MeO compoundsRelease (UK charity)url:a15d151167081306weakconsumedcited only
2019Effects of exposure to 5-MeO-DIPT during adolescence on brain neurotransmission and neurotoxicity in adult ratsNoworyta-Sokolowska K, Kaminska K, Rzemieniec J, Wnuk A, Wojcieszak J, Gorska AM, Kreiner G, Kajta M, Golembiowska K · Forensic Toxicologydoi:10.1007/s11419-018-0433-xmoderateconsumed2 sections
2018Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urineCaspar AT, Gaab JB, Michely JA, Brandt SD, Meyer MR, Maurer HH · Drug Testing and Analysisdoi:10.1002/dta.2197moderateconsumed1 section
2018Prevalence of HIV infection and related risk behaviors among male new-type drug users in Qingdao, Shandong province.Li DM et al. · Zhonghua Liuxingbingxue Zazhidoi:10.3760/cma.j.issn.0254-6450.2018.06.011moderateconsumedcited only
2018The effect of repeated-intermittent exposure to 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) during adolescence on learning and memory in adult rats.Noworyta-Sokołowska K, Górska AM, Gołembiowska K · Pharmacological Reportsdoi:10.1016/j.pharep.2018.04.001moderateconsumed1 section
2016Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.Noworyta-Sokołowska K, Kamińska K, Kreiner G, Rogóż Z, Gołembiowska K · Neurotoxicity Researchdoi:10.1007/s12640-016-9654-0moderateconsumed5 sections
2016Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogensRickli A, Moning OD, Hoener MC, Liechti ME · European Neuropsychopharmacologydoi:10.1016/j.euroneuro.2016.05.001strongconsumed2 sections
2016Recreational drug use and related social factors among HIV-positive men in Japan.Togari T et al. · AIDS Caredoi:10.1080/09540121.2016.1140888moderateconsumed1 section
2015The hallucinogenic world of tryptamines: an updated review.Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M · Archives of toxicologydoi:10.1007/s00204-015-1513-xstrongconsumed1 section
2013Prolonged delusional state triggered by repeated ingestion of aromatic liquid in a past 5-methoxy-N,N-diisopropyltryptamine abuser.Fuse-Nagase Y, Nishikawa T · Addiction Science & Clinical Practicedoi:10.1186/1940-0640-8-9weakconsumed2 sections
2011Abuse liability profile of three substituted tryptaminesGatch MB, Forster MJ, Janowsky A, Eshleman AJ · Journal of Pharmacology and Experimental Therapeuticsdoi:10.1124/jpet.111.179705strongconsumed2 sections
2011Clinical toxicology of newer recreational drugs.Hill SL, Thomas SH · Clinical Toxicology (Philadelphia)doi:10.3109/15563650.2011.615318moderateconsumed1 section
2010Psychedelics and the human receptoromeRay TS · PLoS ONEdoi:10.1371/journal.pone.0009019moderateconsumed1 section
2008Indolealkylamines: biotransformations and potential drug-drug interactionsYu AM · The AAPS Journaldoi:10.1208/s12248-008-9028-5moderateconsumed4 sections
2008Neuropsychotoxicity of abused drugs: molecular and neural mechanisms induced by methamphetamine, MDMA, and 5-MeO-DiPT.Nakagawa T, Kaneko S · Journal of Pharmacological Sciencespmid:18198474moderateconsumed2 sections
2006Designer drugs as a cause of homicide.Matsumoto T, Okada T · Addictiondoi:10.1111/j.1360-0443.2006.01573.xweakconsumed2 sections
2006Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH · Pharmacology, Biochemistry, and Behaviorpmid:16460788moderateconsumed3 sections
2006Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.Narimatsu S, Yonemoto R, Saito K, et al. · Biochemical Pharmacologypmid:16510126moderateconsumed4 sections
2005Foxy methoxy: a new drug of abuse.Smolinske SC, Rastogi R, Schenkel S · Journal of Medical Toxicologypmid:18072099weakconsumed3 sections
2004A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS.Vorce SP, Sklerov JH · Journal of analytical toxicologypmid:15516287moderateconsumed2 sections
Show all 39 sources — 9 more
Sources 31 to 39
yearsourcetierstatusfeeds
2004Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.DEA Deputy Administrator · Federal Registerpmid:15455477moderateconsumed2 sections
20035-MeO-DiPT Basics (Erowid)Erowidurl:3b5e662beee146a6weakconsumedcited only
2003Foxy Fast Facts (National Drug Intelligence Center)US DOJ/NDICurl:9892e09d170feef9weakconsumedcited only
2003Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule.DEA Deputy Administrator · Federal Registerpmid:12678045moderateconsumed1 section
2000The paradox of 5-methoxy-N,N-dimethyltryptamine: an indoleamine hallucinogen that induces stimulus control via 5-HT1A receptors.Winter JC, Filipink RA, Timineri D, Helsley SE, Rabin RA · Pharmacology, Biochemistry, and Behaviorpmid:10638639moderateconsumedcited only
1980N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity.Shulgin AT, Carter MF · Communications in Psychopharmacologypmid:6949674moderateconsumed2 sections
—Searched ClinicalTrials.gov for "5-MeO-DiPT foxy methoxy tryptamine" — no resultsabsenceno results—
—Searched PubMed for "5-MeO-DIPT SERT 5-HT2A 5-HT1A receptor" — no resultsabsenceno results—
—Searched PubMed for "5-methoxy-N,N-diisopropyltryptamine receptor binding serotonin affinity" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-04-26revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki)

    psx:substance/5-meo-dipt/version/1
  2. 0022026-06-04proposal29 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    29 items in this filing

    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · plateau
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · oral
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    • contraindication · psychiatric
    • contraindication · psychiatric
    • contraindication · metabolic
    • contraindication · cardiovascular
    • contraindication · pregnancy_breastfeeding
    • contraindication · neurological
    • contraindication · psychiatric
    psx:substance/5-meo-dipt/proposal/dose_tier/cecbf224-5605-49b3-b3e0-9a32cc8c5935
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/5-meo-dipt/pub/c4e3960c-db63-4693-8b50-fc0b48041b2a

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
emergencyc15c760aabf6f0fcf5b6fc6b…2026-10-19 20:30Revision 1current
info_cardfde2b9b993c12e7c46227aa3…2026-10-19 20:30Revision 1current
emergency3f0909c25c714d225b4bb3e3…2026-09-04 04:28Revision 1superseded2026-10-19
info_cardc16ade557a55455a457f6dde…2026-09-04 04:28Revision 1superseded2026-10-19
noticec5e98aeaee016efdd2256258…2026-09-04 04:28Revision 1current